Literaturverzeichnis

1. Henderson RA, Finn OJ. 1996. Human tumor antigens are ready to fly. Adv. Immunol. 62: 217-256

2. Renkvist N, Castelli C, Robbins PF, Parmiani G. 2001. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50: 3-15

3. Wang RF, Rosenberg SA. 1999. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170: 85-100

4. Banchereau J, Steinman, RM. 1998. Dendritic cells and the control of immunity. Nature. 392: 245-252

5. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D, Schuler G. 1996. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods. 196: 137-151

6. Sahin U, Türeci Ö, Pfreundschuh M. 1997. Serological identification of human tumor antigens. Curr. Opin. Immunol. 9: 709-716

7. Chen YT. 2000. Cancer vaccine: identification of human tumor antigens by SEREX. Cancer J. 6: S208-217

8. Boon T. 1993. Tumor antigens recognized by cytolytic T lymphocytes - present perspectives for specific immunotherapy. (Review). Int. J. Cancer. 54 : 177-180

9. Li Y, McGowan P, Hellstrom I, Hellstrom KM, Chen L. 1994. Costimulation of tumor -reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153: 421-428

10. Weaver CT, Unanue ER. 1990. The costimulatory function of antigen- presenting cells. Immunol. Today 11: 49-55

11. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG. 1999. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 15: 5160-5168

12. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, deCock KA, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijfhout JW, Ottenhoff TH, Offringa R, Melief CJ. 1998. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res. 58: 724-731

[Seite 23↓]

13. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze WJ, Falo LD Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183: 283-287

14. Abe A, Emi N, Taji H, Kasai M, Kohno A, Saito H. 1996. Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy. Gene Ther. 3: 988-993

15. White SA, LoBuglio AF, Arani RB, Pike MJ, Moore SE, Barlow DL, Conry RM. 2000. Induction of anti-tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine. J. Gene Med. 2: 135-140

16. Johnen H, Kulbe H, Pecher G. 2001. Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1) Cancer Immunol. Immunother. 50: 356-360

17. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW. 1999. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59: 676-683

18. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. 1996. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated Antigen. J. Immunol. 156: 224-231

19. Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, Bander NH, Gansbacher B. 1992. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res. 15: 6229-6236

20. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328-332

21. Scheibenbogen C, Schmittel A, Keilholz U, Allgauer T, Hofmann U, Max R, Thiel E, Schadendorf D. 2000. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother. 23: 275-281

22. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. 1996. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63: 298-304

23. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2: 52-58

24. Barratt-Boyes SM, Vlad A, Finn OJ. 1999. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell

[Seite 24↓]

responses. Clin. Cancer Res. 5: 1918-1924

25. Gong J, Chen D, Kashiwaba M, Kufe D. 1997. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3: 558-561

26. Henderson RA, Nimgaonkar MT, Watkins SC, Robbins PD, Ball ED, Finn OJ. 1996. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res. 56: 3763-3770

27. Aicher A, Westermann J, Cayeux S, Willimsky G, Daemen K, Blankenstein T, Uckert W, Dorken B, Pezzutto A. 1997. Successful retroviral mediated transduction of a reporter gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells. Exp. Hematol. 25: 39-44

28. Szabolcs P, Gallardo HF, Ciocon DH, Sadelain M, Young JW. 1997. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Blood. 90: 2160-2170

29. Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL. 1999. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 163: 699-707

30. Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS. 1998. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J. Immunol. 161: 5607-5613

31. Gong J, Chen L, Chen D, Kashiwaba M, Manome Y, Tanaka T, Kufe D. 1997. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther. 4: 1023-1028

32. Dietz AB, Vuk-Pavlovic S. 1998. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood. 91: 392-398

33. Pecher G, Spahn G, Schirrmann T, Kulbe H, Ziegner M, Schenk JA, Sandig V. 2001. Mucin (MUC1) gene transfer into human dendritic cells by cationic liposomes or recombinant adenovirus. Anticancer Res. 21: 2591-2596

34. Diebold SS, Kursa M, Wagner E, Cotten M, Zenke M. 1999. Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J. Biol. Chem. 274: 19087-19094

35. Zheng L, Huang XL, Fan Z, Borowski L, Wilson CC and Rinaldo CRJ. 1999. Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses. AIDS Res. Hum. Retroviruses. 15: 1011-1020

36. Alijagic S, Moller P, Artuc M, Jurgovsky K, Czarnetzki BM, Schadendorf D. 1995.

[Seite 25↓]

Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur. J. Immunol. 25: 3100-3107

37. Pecher G, Häring A, Kaiser L, Thiel E. 2002. Mucin gene (MUC1) transfected dendritic cells as vaccine - results from a phase I / II clinical trial, Cancer Immunol. Immunother. in press, published online 19. 10. 02

38. Ron Y, Sprent J. 1987. T cell priming in vivo : a major role for B cells in presenting antigen to T cells in lymph nodes. J. Immunol. 138: 2848-2856

39. Finkelman FD, Lees A, Morris SC. 1992. Antigen presentation by B Lymphocytes to CD4+ T lymphocytes in vivo: Importance for B lymphocyte and T lymphocyte activation. Sem. Immunol. 4: 247-255

40. Boussiotis VA, Freeman GJ, Gribben JG, Daley J, Gray G, Nadler LM. 1993. Activared human B lymphocytes express three CTLA 4 counter receptors that co-stimulate T cell activation. Proc. Natl. Acad. Sci. USA 90: 11059-11063

41. Jerome KR, Bu D, Finn OJ. 1992. Expression of tumor-associated epitopes on Epstein-Barr-Virus-immortalized B-cells and Burkitt's Lymphomas transfected with epithelial mucin complementary DNA. Cancer Res. 52: 5985-5990

42. Pecher G, Finn OJ. 1996. Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA transfected EBV-immortalized autologous B cells. Proc. Natl. Acad. Sci. USA. 93: 1699-1704

43. Kubuschok B, Schmits R, Hartmann F, Cochlovius C, Breit R, Konig J, Pistorius G, Schilling M, Renner C, Pfreundschuh M. 2002. Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model. Hum. Gene Ther. 13: 815-827

44. Chen CH, Wang TL, Hung CF, Pardoll DM, Wu TC. 2000. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine. 18: 2015-2022

45. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE. 1998. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90: 1894-1900

46. Lekutis C, Shiver JW, Liu MA, Letvin NL. 1997. HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha. J. Immunol. 158: 4471-4477

47. Christ M, Lusky M, Stoeckel F, Dreyer D, Dieterle A, Michou AI, Pavirani A, Mehtali M. 1997. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol. Lett. 57: 19-25

[Seite 26↓]

48. Nunes FA, Furth EE, Wilson JM, Raper SE. 1999. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum. Gene Ther. 10: 2515-2526

49. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. 1997. DNA vaccines. Ann. Rev. Immunol. 15: 617-648

50. Wild J, Gruner B, Metzger K, Kuhrober A, Pudollek HP, Hauser H, Schirmbeck R, Reimann J. 1998. Polyvalent vaccination against hepatitis B surface and core antigen using a dicistronic expression plasmid. Vaccine. 16: 353-360

51. Martin T, Parker SE, Hedstrom R, Le T, Hoffman SL, Norman J, Hobart P, Lew D. 1999. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum. Gene Ther. 10: 759-768

52. Krieg AM. 1999. Direct immunologic activities of CpG DNA and implications for gene therapy. J. Gene Med. 1: 56-63

53. Jahrsdorfer B, Hartmann G, Racila E, Jackson W, Muhlenhoff L, Meinhardt G, Endres S, Link BK, Krieg AM, Weiner GJ. 2001. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J. Leukoc. Biol. 69: 81-88

54. Schirmbeck R, Reimann J. 2001. Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12. Intervirology. 44: 115-123

55. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G. 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 31: 2154-2163

56. Sedegah M, Weiss W, Sacci JB Jr, Charoenvit Y, Hedstrom R, Gowda K, Maja VF, Tine J, Kumar S, Hobart P, Hoffman SL. 2000. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J. Immunol. 164: 5905-5912

57. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, Wu TC. 2000. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60: 1035-1042

58. Gendler SJ, Burchell JM, Duhig T. 1987. Cloning of a partial cDNA encoding differentiation and tumor -associated mucin glycoproteins expressed by human mammary epithelium. Proc. Natl. Acad. Sci. USA. 84: 6060-6064

59. Gendler SJ , Lancaster CA, Taylor- Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D. 1990. Molcular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 265: 15286-15293

[Seite 27↓]

60. Lan MS, Batra SK, Qi WN, Metzgar RS, Hollingsworth MA. 1990. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J. Biol. Chem. 265: 15294-15299

61. Hakomori S. 1989. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Canc. Res. 52: 257-331

62. Chen C, Fenderson BA, Andrews PW, Hakomori S. 1989. Glycolipid glycosyltransferases in human embryonal carcinoma cells during retinoic acid induced differentiation. Biochemistry. 28: 2229-2238

63. Itzkowitz S, Kjeldsen T, Friera A, Hakomori SI, Yang US , Kim YS. 1991. Expression of Tn sialosyl, Tn and T antigens in human pancreas. Gastroenterology. 100: 1691-1700

64. Finn OJ. 1992. Pancreatic tumor antigen: diagnostic markers and targets for immunotherapy (Review). Import. Advanc. Oncology. 61-77

65. Rughetti A, Turchi V, Ghetti CA, Scambia G, Panici PB, Ronucci G, Mancuso S, Frati L, Nuti M. 1993. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res. 53: 2457-2459

66. Xing P.X, Reynolds K, Tjandra JJ, Tang XL, McKenzie IF . 1990. Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies. Cancer Res. 50 : 89-96

67. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J, Barratt-Boyes SM. 1996. MUC-1 epithelial tumor-mucin-based immunity and cancer vaccines. Immunol. Rev. 145: 61-89

68. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. 1993. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151: 3693-3703

69. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A. 1994. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J. Immunol. 153: 2102-2109

70. Barnd DL., Kerr LA, Metzgar RS, Finn OJ. 1988. Tumor-specific cytotoxic T cell lines generated from tumor draining lymph node infiltrate. Transpl. Proc. 20: 339-341

71. Jerome K, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IFC, Bast RC, Finn OJ. 1991. Cytotoxic T- lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of mucin molecule preferentially expressed by malignant cells. Cancer Res. 51: 2908-2916

72. Burchell J, Gendler S, Taylor- Papadimitriou J, Girling A , Lewis A, Millis R, Lamport D. 1987. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 47 : 5476-5482

[Seite 28↓]

73. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. 1989. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Canc. 43: 1072-1076

74. Burchell J, Durbin H, Taylor-Papadimitriou J. 1983. Complexity of expression of antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells. J. Immunol. 131: 508-513

75. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. 1994. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res. 54: 2856-2860

76. Ding L, Lalani EN, Reddish M, Koganty R, Wong T, Samuel J, Yacyshyn MB, Meikle A, Fung PYS, Taylor-Papadimitriou J, Longenecker MB. 1993. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC 1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. 36 : 9-17

77. Barnd DL, Lan MS, Metzgar RS, Finn OJ. 1989. Specific, MHC- unrestricted recognitation of tumor associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA 86 : 7159-7163

78. Finn O. J. 1992. Antigen -specific , MHC- unrestricted T cells. (Review). Biotherapy. 4 : 239-249

79. Magarian-Blander J, Ciborowski P, Hsia S, Watkins SC, Finn OJ. 1998. Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1. J. Immunol. 160: 3111-3120

80. Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF. 1997. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. 159: 5211-5218

81. Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF. 2000. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine. 18: 2059-2071

82. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W. 1999. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood. 93 : 4309-4317

83. McKolanis JR, Finn OJ. 2000. Analysis of the frequency of MHC-unrestricted MUC1-specific cytotoxic T-cells in peripheral blood by limiting dilution assay. Methods Mol Biol. 125: 463-470

84. Kuan SF, Byrd JC, Basbaum C, Kim S. 1989. Inhibition of mucin glycosylation by Aryl-N-acetyl-a-galactosaminides in human colon cancer cells. J. Biol. Chem. 264 :

[Seite 29↓]

19271-19277

85. Ben-Mahrez K, Sorokine I, Thierry D, Kawasumi T, Ishii S, Salmon R, Kohiyama M. 1990. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int. J. Cancer. 15: 35-38

86. Pupa SM, Menard S, Andreola S, Colnaghi MI. 1993. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res. 53: 5864-5866

87. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, et al. 1994. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54: 16-20

88. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. 1992. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 52: 4168-4174

[Seite 30↓] Publikationen

1. Pecher G. and O. J. Finn. 1996. Induction of cellular immunity in chimpanzees to tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected EBV-immortalized autologous B cells. Proc. Natl. Acad. Sci. USA. 93:1699-1704

2. Kotera Y., J. D. Fontenot, G.Pecher, R. S. Metzgar, and O. J. Finn. 1994. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res. 54: 2856-2860

3. Jerome K. R., A. D. Kirk, G. Pecher, W. W. Ferguson, and O. J. Finn. 1997. A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis. Cancer Immunol. Immunother. 43: 355-360

4. Kilger E.*, G. Pecher*, A. Schwenk and W. Hammerschmidt. 1999. Expression of Mucin (MUC-1) from a Mini-Epstein-Barr Virus in immortalized B-cells to generate tumor antigen specific cytotoxic T cells. J. Gene Med. 1: 84-92 * joined first authorship

5. Pecher G., Harnack U., Günther M., Hummel M., Fichtner I., and J. A. Schenk. 2001. Generation of an immortalized human CD4+ T cell clone inhibiting tumor growth in mice. Biochem. Biophys. Res. Comm. 283:738-742

6. H. Johnen, H. Kulbe and G. Pecher. 2001. Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1) Cancer Immunol. Immunother . 50: 356-360

7. Pecher G., Spahn G., Schirrmann T., Kulbe H., Ziegner M., Schenk J.A., and V. Sandig. 2001. Mucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirus. Anticancer Res. 21: 2591-2596

8. Pecher G., Schirrmann T., L. Kaiser L. and J.A. Schenk. 2001. Efficient cryopreservation of dendritic cells transfected with cDNA of a tumour antigen for clinical application. Biotechnol. Appl. Biochem. 34:161-166

9. Pecher G., A. Häring, L. Kaiser and E. Thiel. 2002. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I / II clinical trial, Cancer Immunol Immunother, in press, published online 19. 10. 2002